Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Axovant Sciences Ltd. (NASDAQ: AXON).

Full DD Report for AXON

You must become a subscriber to view this report.


Recent News from (NASDAQ: AXON)

Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, ...
Source: SeekingAlpha
Date: May, 14 2018 12:27
Premarket Losers as of 9:05 am (5/8/2018)
ARLZ   -26%  on terminating U.S. operations. More news on: Aralez Pharmaceuticals Inc., Nevro, Nobilis Health Corp., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 08 2018 09:19
Midday Gainers / Losers (05/07/2018)
Gainers: BLNK +184% . XTLB +92% . NFEC +24% . AGMH +21% . AXON +18% . VVPR +19% . ATHN +16% . GPT +15% . NCMI +15% . TWIN +15% . More news on: Blink Charging Co., XTL Biopharmaceuticals Ltd., NF Energy Saving Corp., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 07 2018 12:47
vTv Therapeutics Fails Late-Stage Alzheimer's Study; Is There A Chance For A Comeback?
Recently, vTv Therapeutics ( VTVT ) announced data from its phase 3 trial treating patients with mild Alzheimer's. It stated that it had failed to meet on both co-primary endpoints of the study. That led to the stock closing lower by 78% on Tuesday. While the drop in share price was a big one,...
Source: SeekingAlpha
Date: April, 16 2018 16:02
Midday Gainers / Losers (04/11/2018)
Gainers: LEDS +47% . PVG +19% . AVAV +18% . CELH +17% . VHC +13% . AAOI +14% . EYPT +13% . CBAY +13% . OTCQB:AMRH +13% . AXON +12% . More news on: SemiLEDs Corporation, Pretium Resources Inc, AeroVironment, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 11 2018 12:50
Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data
A nalysis focus: vTv Therapeutics Today we will discuss vTv Therapeutics (VTVT), which has seen three quarters of its market capitalization wiped off after the failure of a late-stage Alzheimer’s study. The failure once again highlights the fact that Alzheimer’s rema...
Source: SeekingAlpha
Date: April, 11 2018 08:00
Oryzon Genomics on go with mid-stage study of Alzheimer's candidate ORY-2001
Madrid, Spain-based Oryzon Genomics announces that it has received regulatory sign-off for a Phase 2a clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: Alzheon, Denali Therapeutics, Inc., Wave Life Sciences, Healthcare stocks news...
Source: SeekingAlpha
Date: April, 04 2018 11:14
Celgene Vs. Biogen: Both Are A Steal, But Which One Is Better?
Today, we are going to take a look at Celgene ( CELG ) and Biogen ( BIIB ), two comparable biopharmaceutical companies with a market capitalization of $67 billion and $60 billion, respectively. Celgene's stock is trading near a three-year low while Biogen's stock is also near a 52-week low. In...
Source: SeekingAlpha
Date: March, 05 2018 12:23
Axovant Sciences: 5 Trials, 4 Failures - Expect A Fifth
Intepirdine On September 26, 2017 , Axovant's stock price tanked 70% upon news of their first Alzheimer's phase 3 trial failure for their flagship drug Intepirdine. Then, on January 8, 2018, the company's stock tanked another 53% after an 8-K released by the company announced that dev...
Source: SeekingAlpha
Date: February, 25 2018 20:26
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2017 Update
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's US stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 02/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global ...
Source: SeekingAlpha
Date: February, 22 2018 11:53

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-171.241.231.241.19305,896
2017-06-2021.6323.1223.739921.315793,061
2017-06-1921.1821.5221.8921.01331,914
2017-06-1620.6121.0321.3520.12512,248
2017-06-1523.1020.7223.2820.53950,173

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1744,16779,53655.5308Short
2018-08-1698,671148,33766.5181Short
2018-08-15249,612423,63058.9222Short
2018-08-14140,218209,44466.9477Short
2018-08-1383,852174,35748.0921Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AXON.


About Axovant Sciences Ltd. (NASDAQ: AXON)

Logo for Axovant Sciences Ltd. (NASDAQ: AXON)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $132,579,331 - 05/14/2018
  • Issue and Outstanding: 107,788,074 - 02/08/2018

 


Recent Filings from (NASDAQ: AXON)

Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: March, 14 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: March, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 09 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: January, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 21 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 06 2017
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: November, 29 2017
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: November, 17 2017

 

 


Daily Technical Chart for (NASDAQ: AXON)

Daily Technical Chart for (NASDAQ: AXON)


Stay tuned for daily updates and more on (NASDAQ: AXON)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AXON)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AXON is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AXON and does not buy, sell, or trade any shares of AXON. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/